⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13072951 | 0.79 | — | — | |
| SCHEMBL27038933 | 0.77 | — | — | |
| SCHEMBL29894839 | 0.76 | CA1 (0.50) | — | |
| SCHEMBL5702570 | 0.76 | CA1 (0.50) | — | |
| SCHEMBL1179274 | 0.74 | — | — | |
| SCHEMBL63365 | 0.74 | CHRNB4 (0.49) | — | |
| SCHEMBL29612256 | 0.74 | CHRNB4 (0.49) | — | |
| SCHEMBL30711544 | 0.74 | — | — | |
| SCHEMBL7055362 | 0.74 | PLAU (0.44) | — | |
| SCHEMBL8502454 | 0.73 | PLAU (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | claimed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3849983-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-07-21 | — | — | EP | claimed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | claimed |
| CN-112384515-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2021-02-19 | — | — | CN | claimed |
| CN-112313234-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-02-02 | — | — | CN | claimed |
| EP-3759112-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-01-06 | — | — | EP | claimed |
| WO-2020052631-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-03-19 | — | — | WO | claimed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | claimed |
| US-10154995-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-18 | — | — | US | claimed |
| EP-3089788-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | claimed |
| US-20170348310-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-07 | — | — | US | claimed |
| US-9763942-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | claimed |
| EP-3089788-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160303126-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103133-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-09 | — | — | WO | claimed |
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-4826814-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-05-02 | — | — | US | disclosed |
| EP-0244836-A2 | Tripeptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-11 | — | — | EP | disclosed |